The bottom line: "Prophylactic cranial irradiation in stage III NSCLC significantly decreases the risk of brain metastases without improving 1-year overall survival. There were no significant differences in global cognitive function or quality of life after prophylactic cranial irradiation, but there was a significant decline in memory at 1 year."
http://www.ncbi.nlm.nih.gov/pubmed/21135267
J Clin Oncol. 2010 Dec 6. [Epub ahead of print]
Phase III Trial of Prophylactic Cranial Irradiation Compared With Observation in Patients With Locally Advanced Non-Small-Cell Lung Cancer: Neurocognitive and Quality-of-Life Analysis.
Sun A, Bae K, Gore EM, Movsas B, Wong SJ, Meyers CA, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H.
Princess Margaret Hospital-University Health Network, University of Toronto, Toronto, Ontario, Canada; Radiation Therapy Oncology Group; Thomas Jefferson University Hospital, Philadelphia, PA; Henry Ford Health System; Medical College of Wisconsin, Milwaukee, WI; MD Anderson Cancer Center, Houston; University of Texas Southwestern Medical Center, Dallas, TX; University of Alabama at Birmingham, Birmingham, AL; Mayo Clinic Arizona, Scottsdale, AZ; University of Colorado Cancer Center, Aurora, CO; and the State University of New York Health Science Center at Syracuse, Syracuse, NY.
No comments:
Post a Comment